In contrast to neoantigen-based vaccines, which focus on targeting mutation-specific antigens unique to individual tumors, our multi-epitope vaccine targets conserved tumor-associated antigens (DKKL1, FBXO39, and OIP5) that are widely expressed across CRC patients. Here, FBXO39 is linked to neoplasm.